Drug Profile
Research programme: MBL inhibitors - UniQuest
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Bacterial-infections(Adjuvant therapy) in Australia
- 03 Aug 2016 Research programme: MBL inhibitors - UniQuest is available for licensing -http://uniquest.com.au/filething/get/15614/Cu-Carbapenem%20Marketing%20Sheet%20v5.pdf
- 03 Aug 2016 Early research in Bacterial infections (Adjuvant therapy) in Australia (unspecified route)